XKRX:019170 (Korea (the Republic of))
Â
â‚©
11990.00
(+0.25%)
Jun 24
Current and historical daily PE Ratio for Shinpoong Pharmaceutical Co Ltd (
XKRX:019170
) from 1990 to Jun 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Shinpoong Pharmaceutical stock (XKRX:019170) PE ratio as of Jun 25 2024 is 0.
More Details
Shinpoong Pharmaceutical Co Ltd (XKRX:019170) PE Ratio (TTM) Chart
Shinpoong Pharmaceutical Co Ltd (XKRX:019170) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1280
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| Shinpoong Pharmaceutical PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-25 | At Loss | 2024-04-17 | At Loss |
| 2024-06-24 | At Loss | 2024-04-16 | At Loss |
| 2024-06-21 | At Loss | 2024-04-15 | At Loss |
| 2024-06-20 | At Loss | 2024-04-12 | At Loss |
| 2024-06-19 | At Loss | 2024-04-11 | At Loss |
| 2024-06-18 | At Loss | 2024-04-09 | At Loss |
| 2024-06-17 | At Loss | 2024-04-08 | At Loss |
| 2024-06-14 | At Loss | 2024-04-05 | At Loss |
| 2024-06-13 | At Loss | 2024-04-04 | At Loss |
| 2024-06-12 | At Loss | 2024-04-03 | At Loss |
| 2024-06-11 | At Loss | 2024-04-02 | At Loss |
| 2024-06-10 | At Loss | 2024-04-01 | At Loss |
| 2024-06-07 | At Loss | 2024-03-29 | At Loss |
| 2024-06-05 | At Loss | 2024-03-28 | At Loss |
| 2024-06-04 | At Loss | 2024-03-27 | At Loss |
| 2024-06-03 | At Loss | 2024-03-26 | At Loss |
| 2024-05-31 | At Loss | 2024-03-25 | At Loss |
| 2024-05-30 | At Loss | 2024-03-22 | At Loss |
| 2024-05-29 | At Loss | 2024-03-21 | At Loss |
| 2024-05-28 | At Loss | 2024-03-20 | At Loss |
| 2024-05-27 | At Loss | 2024-03-19 | At Loss |
| 2024-05-24 | At Loss | 2024-03-18 | At Loss |
| 2024-05-23 | At Loss | 2024-03-15 | At Loss |
| 2024-05-22 | At Loss | 2024-03-14 | At Loss |
| 2024-05-21 | At Loss | 2024-03-13 | At Loss |
| 2024-05-20 | At Loss | 2024-03-12 | At Loss |
| 2024-05-17 | At Loss | 2024-03-11 | At Loss |
| 2024-05-16 | At Loss | 2024-03-08 | At Loss |
| 2024-05-14 | At Loss | 2024-03-07 | At Loss |
| 2024-05-13 | At Loss | 2024-03-06 | At Loss |
| 2024-05-10 | At Loss | 2024-03-05 | At Loss |
| 2024-05-09 | At Loss | 2024-03-04 | At Loss |
| 2024-05-08 | At Loss | 2024-02-29 | At Loss |
| 2024-05-07 | At Loss | 2024-02-28 | At Loss |
| 2024-05-03 | At Loss | 2024-02-27 | At Loss |
| 2024-05-02 | At Loss | 2024-02-26 | At Loss |
| 2024-04-30 | At Loss | 2024-02-23 | At Loss |
| 2024-04-29 | At Loss | 2024-02-22 | At Loss |
| 2024-04-26 | At Loss | 2024-02-21 | At Loss |
| 2024-04-25 | At Loss | 2024-02-20 | At Loss |
| 2024-04-24 | At Loss | 2024-02-19 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
Shinpoong Pharmaceutical Co Ltd (XKRX:019170) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Shinpoong Pharmaceutical Co Ltd
NAICS : 325412
ISIN : KR7019170000
Compare
Compare
Traded in other countries / regions
019170.Korea IPO Date
1990-01-20Description
Shinpoong Pharmaceutical Co Ltd specializes in manufacturing remedy drugs and also active pharmaceutical ingredients and finished products. Its products include Newsicam, Caravenal, Roxagen, Clamoxin duo, Ceroxim, and Clocin. The firm's production facilities are located at Gyeonggi-do and Cheongwon-gun.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers